Information Provided By: 
Fly News Breaks for August 14, 2018
TXMD
Aug 14, 2018 | 07:09 EDT
Cantor Fitzgerald analyst William Tanner raised his price target for TherapeuticsMD to $27 from $26 following the approval of Annovera, which he says "provides another leg to the TXMD stool." The company's acquisition of commercial rights to Annovera should appeal to investors, Tanner tells investors in a research note. He believes the product is "clearly complementary" to the emerging women's health franchise. The analyst thinks he next 12-18 months could be a period of positive stock performance if TherapeuticsMD executes on the commercial front.
News For TXMD From the Last 2 Days
There are no results for your query TXMD
